Share this video  

ASCO GI 2023 | Highlights in gastric and colorectal cancer at ASCO GI 2023

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on his highlights presented at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including findings from the SPOTLIGHT trial (NCT03504397) of zolbetuximab in gastric and gastroesophageal junction (GEJ) cancer, as well as the SUNLIGHT trial (NCT04737187) of trifluridine and tipiracil with bevacizumab in metastatic colorectal cancer. Additional highlights include the use of regorafenib as second-line therapy in gastric cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.